I n July, NHS England in partnership with NHS Clinical Commissioners (NHSCC, the national representative organisation for CCGs), published a consultation document outlining new national commissioning guidance for CCGs throughout England. 1 The consultation document followed extensive work carried out by an NHS England/NHSCC joint clinical working group, who identified a list of 18 itemswhich currently cost the NHS over £140 million -they consider of "low clinical value" and that they feel should not routinely be prescribed in primary care. On reaching their proposed recommendations, the working group considered evidence from several sources including NICE guidance, PrescQIPP evidence reviews, advice from the Medicines and Healthcare products Regulatory Agency (MHRA) and the BNF.
The items up for consultation fall into one of three categories: low clinical effectiveness or significant safety concerns; clinically effective but more cost-effective products are available; and clinically effective, but deemed a low priority for NHS funding (see Table 1 ). In most cases, the proposed advice to CCGs is that the item should not be initiated in any new patient, and that prescribers should be supported in deprescribing the item in all patients. However, in some cases, the item can still be prescribed in primary care in exceptional circumstances if there is a clinical need, but this should be undertaken in co-operation with other healthcare professionals.
NHS England/NHSCC say that the objective of the guidance is to "support CCGs in their decision-making, to address unwarranted variation and to provide clear national advice to make local prescribing practices more effective." In addition, the associated cost savings form an important component of the 10-point efficiency plan outlined in the NHS's Next Steps on the NHS Five Year Forward View. 2 The consultation period ends in late October, and NHS England/NHSCC will then assimilate the views of patient representative bodies, charities, royal colleges and industry as well as CCGs before formulating final guidance. Once published, CCGs will be expected to take the final guidance into account when formulating local policies. However, NHS England/NHSCC emphasise that the guidance "does not remove the clinical discretion of the prescriber."
Items of low clinical value
So, how were the first 18 items of low value chosen? Julie Wood, chief executive, NHSCC says: "Our work is wholly driven by our members. In this case, following discussion at our medicines task group which, among others, brings together heads of CCG medicines management, chief clinical officers and pharmacists, we began to work with PrescQIPP , who were already looking at prescribable items that could potentially be considered low priority for funding. We tested initial findings with our membership through a survey, webinar and direct engagement, producing some recommendations for discussion with NHS England.
After subsequent discussions, we agreed to include in the final consultation document 18 items where the most value could be released for the NHS." However, some of the items identified have caused ripples of concern among prescribing professionals, for example the painkiller co-proxamol. "When the licence for co-proxamol was withdrawn in 2005, assurances were given to people whose pain could not be controlled by other products that they would still be able to receive it," says Bath-based Matt Griffiths, an independent consultant nurse and visiting professor of prescribing and medicines management. "Most patients were switched to other medications, but some needed to continue on the co-proxamol." On immediate-release fentanyl, he adds: "Patients won't usually be placed on it as a first-line medication but may be given it as a second-or thirdline treatment when first-line treatments haven't been successful."
The inclusion of homeopathy, on the other hand, is likely to have the support of many healthcare professionals. For example, the Royal Pharmaceutical Society welcomes its inclusion, saying that: "Removing homeopathy, which has no scientific or pharmacological basis, from NHS supply is long overdue."
Gluten-free foods
Gluten-free foods are also mentioned in the consultation document but are not specifically included as an item for consultation, because the Department of Health has recently conducted a separate consultation on changes to the availability of gluten-free products on prescription in primary care. 3 their support to end the prescribing of gluten-free products in primary care, which cost the NHS £26 million a year. The consultation closed in June and outcomes and recommendations are expected shortly. Gluten-free foods have been available on prescription since the late 1960s and although the availability of gluten-free products has greatly improved in recent years, Coeliac UK says that vulnerable groups could suffer as a result of restricting their availability on prescription. "Poorer groups aren't always able to access the out-of-town, better-stocked supermarkets," says Norma McGough, the charity's director of policy, research and campaigns. "Already under localised policy making in England we have seen some CCGs remove access to gluten-free foods on prescription, and our research shows that when this happens, people across all income brackets spend £10 a week more on food, which can equate to 25% of the weekly food budget in lowincome families."
Moreover, adds Ms McGough, there are serious consequences if people with coeliac disease can't afford the gluten-free products they need. "If you look at some of the complications of not adhering to a gluten-free diet -osteoporosis, which increases the risk of spinal and hip fracture, for example -there is going to be a much more significant impact on the NHS budget in the long term, not to mention the suffering that people go through."
Over-the-counter medicines
In addition to the 18 items of low clinical value currently under review, the NHS England/NHSCC working group have also identified over 3200 further items that are at present prescribable in primary care but that they consider of low priority for NHS funding, which will be considered in the next phase of their review. These are items that are available to purchase over the counter in pharmacies or in convenience stores, and which currently cost NHS England a massive £645 million in prescriptions. This includes treatment for conditions such as headache, fever, athlete's foot, constipation, head lice and cold sores, which NHS England/NHSCC say can be considered self-limiting and lend themselves to self-care. Examples of items they propose should be included in the review are listed in Table 2 . At this stage, there are no proposed specific recommendations on these items in the consultation document, and the working group is only seeking general views, which will inform future detailed guidance for further consultation.
Nevertheless, the issue has already caused some apprehension among health professionals. For example, the Royal Pharmaceutical Society has expressed serious concerns about restricting the prescription of clinically effective medicines, such as treatments for head lice or athlete's foot, as this disregards the NHS principle that care should be free at the point of delivery. Says RPS England board chair Sandra Gidley: "Expecting everyone to pay for medicines for common conditions will further increase health inequalities and worsen the health of patients who cannot afford them... Longer term costs to the taxpayer of increased ill-health, subsequent GP consultations or visits to A&E must also be taken into account as a result of medicines not having been prescribed."
Conversely, some GPs are concerned that this part of the commissioning guidance will not go far enough, and that proper legislation is needed on the prescribing of over-the counter medicines. For example, in the current consultation document, it is proposed that CCGs will still need to take individual decisions on implementation locally, taking into account their duties to advance equality and reduce health inequality. There is also the possibility that the guidance will allow some items to be prescribed in primary care in exceptional circumstances. Many GPs believe this will result in them taking the brunt of difficult conversations with patients. At the Pulse Live conference in London in March this year, more than 65% of delegates in a show of hands vote expressed support for an actual ban on all over-the-counter prescribing by GPs.
"If they're going to stop GPs prescribing certain things then they need to be blacklisted through a change in legislation, and politicians will need to bear a public backlash," says Dr Andrew Green prescribing lead at the BMA's General Practitioners Committee. "We think 'guidance' from NHS England and CCGs is inadequate, as the patient can still demand over-the-counter treatments from their GP and complain if they don't get them." Dr Green continues: "GPs have a requirement under their terms of service to prescribe drugs that are needed, and NHS England's attempts to reduce prescribing are at odds with that."
But local CCGs who have already issued guidance to clamp down on prescribing of over-the-counter medicines say they are within the spirit of the BMA's advice that "a patient is entitled to drugs that the GP believes are necessary, not those which the patient feels should be prescribed."
According to Professor Matt Griffiths, CCGs can already save money through the use of formularies, but clinicians need off-formulary options when required, without individual patients needing to apply for individual funding. But he adds that prescribing off formulary when general practices have their own dispensaries or pharmacies, and therefore have a conflict of interest, may be an important issue to examine: "This could potentially save money from the public purse, but may be unpopular with CCGs, as many CCGs have GPs running them, some of whom will have these dispensing or pharmacy services." Among all the differing opinions, promoting self-care among patients by encouraging over-the-counter purchasing is one area that is common ground, though it can be an uphill struggle, given that 88% of prescription items are dispensed free of charge.
"If patients are in a position that they can afford to buy over-the-counter medicines and products, then we would encourage them to do so without a prescription," says Dr Helen Stokes-Lampard, chair of the RCGP . "The difficulty is when people don't pay prescription charges, so they are entitled to free medication on the NHS."
There are other niggles that also need ironing out -for example, patients may be hampered by restrictions that prevent the over-the-counter sale of more than 32 paracetamol at a time, which is just four days' supply at maximum dosage. Potential unintended consequences like GPs prescribing more powerful or more expensive alternatives to common painkillers also needs careful examination.
But if more people do star t to self-medicate minor ailments and con-sult their pharmacist rather than their GP , savings could potentially multiply. "Pharmacists across the country play a vital role in supporting efficient use of medicines, helping to derive the best value from treatments and reducing wastage," says Robbie Turner, director for England, Royal Pharmaceutical Society. "Treating common ailments such as coughs and colds in community pharmacies, rather than in A&E or GP surgeries, could save the NHS £1 billion a year."
Next steps
Once the consultation period has ended, the next step in the process will be for NHS England/NHSCC to analyse and consider all responses received, following which a summary will be published on their websites. It is anticipated that the final commissioning guidance will be published in November, and then if all goes to plan, progress should start to be made in cutting England's rapidly growing drugs bill. Where any cash saved would be most wisely redirected is, of course, a whole new debate.
